# Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

> **NCT00151125** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 12 (actual)

## Conditions studied

- Von Willebrand Disease

## Interventions

- **DRUG:** recombinant interleukin-11
- **DRUG:** recombinant interleukin-11
- **DRUG:** recombinant interleukin-11

## Key facts

- **NCT ID:** NCT00151125
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151125, "Phase II Study of IL-11 (Neumega) in Von Willebrand Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00151125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*